Lonza will work with Iconovo to develop spray-dried formulations for an intranasally delivered biologic using a reformulated biologic drug candidate for obesity.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

With New Funding, Orbis Medicines to Develop Oral Macrocycles as Alternative to Biologic Drugs

By Feliza Mirasol

January 7th 2025

With the new $94 million (€90 million) funding, the company will develop its pipeline of oral macrocycle drugs, nCycles, against validated biologic targets.

Takeda Receives Japanese Regulatory Approval for HYQVIA Subcutaneous Injection for Treating Agammaglobulinemia or Hypogammaglobulinemia

By Feliza Mirasol

January 4th 2025

With this approval, HYQVIA [Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase] becomes the first and only facilitated subcutaneous immunoglobulin available in Japan to treat these disorders.

Orexo and Abera Partner to Develop Nasal Powder Vaccines

By Feliza Mirasol

December 20th 2024

The companies will use Orexo’s powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.

3D printed pills and drugs, future of medicine. 3D Printing Drugs In Pharmacies. Multi-colored, various drugs, pills, capsules. Pharmaceutical medical concept | Image Credit: © irissca - © irissca - stock.adobe.com

Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications

By Gary Ritchie
Sharon Flank

December 10th 2024

This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.

Reshaping Dosage Forms

Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

...

Editorial Advisory Board

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777